Pediatric HSV Encephalitis

Pediatric HSV Encephalitis

Clinical Clues
-Same as adults: T°C, Szs (often focal), AMS, and behavior chx
-What is different? 
< 5yo, unilat facial or perioral twitching was seen in about 1/3 of cases and was linked to frontal/insular involvement and later language problems

Diagnosis
-CSF HSV PCR is the dx standard
> An early ⊖PCR does not r/o HSE
-MRI with DWI, imaging of choice
-EEG→ focal temp slow, PLEDs
-Neonates: also check blood HSV PCR, surface swabs, and ALT

TTx
-Acyclovir 4 mo (20 mg/Kg), 4mo-12yo (15 mg/Kg), > 12y (10 mg/Kg)
-Duration q8h for 21 days
-Renal adjustment
-Main risk: crystal nephropathy causing AKI
-Poor evidence for corticosteroids

Neonatal HSV oral acyclovir suppression after CNS disease
-After IV therapy for neonatal HSV, give oral acyclovir 300 mg/m² per dose three times daily for 6 mo, starting as soon as the IV course ends
-Only acyclovir is approved! Do not give valacyclovir!

Complications and follow-up
-Sequelae are common, 42% cognitive, and 54% post-encephalitic epilepsy

Ophthalmoscope

Ophthalmoscope

Types
-Traditional vs PanOptic

Parts
-Common parts
>Focusing wheel
>Filter

Filters/ Aperture settings
-L/M/S→ match pupil size, MC medium
-Half light→ views around lens opacities (cataract)
-Red-free→ highlights vessels and hemorrhages; Retina is black&white
-Slit beam→ assesses contours and depth
-Blue (Cobalt) light→ detects corneal defects with fluorescein
-Grid→ estimates retinal lesion dimensions

Focusing wheel
-Do not change if normal (20/20) examinator eyes
>Valid for PanOptic, if normal pt eyes
  >For traditional, if abnormal pt eyes, may adjust
  >If pt is extremely near or farsighted, you may adjust for both (PanOptic & Traditional)
>If move and is better, the N is equal to the prescription in diopters
⊕ (Green) = nearer
⊖ (Red) = farther
Light
- Rotate to turn on
- ↑ON = ↑Light = ↑Painful pt

The Two Techniques

-Before techniques, adjust the focus, and also explain to pt

-First (MC)
1. Position the patient so that the ophthalmoscope is held directly at the level of the patient’s eye.
2. Turn on the ophthalmoscope and set the light to the correct aperture. Dim the lights.
3. Instruct the patient to focus on an object straight ahead on the wall.
4. To exam the patient’s RIGHT eye, hold the ophthalmoscope in your RIGHT hand and use your RIGHT eye to look through the instrument.
5.Place your left hand on the patient’s head and place your thumb on their eyebrow.
6. Hold the ophthalmoscope about 6 inches from the eye and 15 degrees to the right of the patient. 
7. Find the red reflex. Move in closer, staying nasally until you see the optic nerve.
8. Rotate the diopter lens until the optic nerve comes into focus.
>The farsighted eye requires more plus/green number lenses.
>The nearsighted eye requires more minus/red number lenses.
9. Measure the cup to disc ratio.
10. Scan slightly up, down, right and left to look at the vessels.
11. Move out temporally to find the macula and fovea.

-Second
1. Stay around 30 cm from the patient
2. Came laterally

-Clues
>First, look at the optic disc
  > If PanOptic, ask for pt, look up-down, lat-lat, look at light (macula)
  >If traditional, you move

LOMEDS

Late-onset myoclonic epilepsy in Down syndrome
DS–associated AD spectrum

Epidemiology
-Age→ 40-50 yo
-Dementia→ AD (overlay path)
*Can occur w/o AD

Clinical Manifestations
-Szs types→ MCL & GTCs
-Three stage by Orsi (aka PME-like course)
1st) EEG abnormal during sleep
2nd) MCL on awake
3rd) Significant burden

DDx
-R/o metabolic causes and DIM

TTx
-DOC is LVT; otherwise, VPA
>If RFx, consider add-on PMP
>Prescribe, BZD rescue
-Avoid Na+ blockers
-OSA mgmt

Prognosis
-↑Mortality & ↑Cognitive decline

Febrile seizure

Febrile seizure

Definition
-Age + T°C + no CNS infection
1st) Age: 6 mo - 5 yo
*>6y→GEFS+
2nd) T ≥ 38°C
3rd) No CNS infection

Epidemiology
-MC szs of childhood
-Peak 1y
-Viral, mainly
>can occur after DTP (1d) or MMR (8d)
-Genetic, 25% FH of szs (FS or Epi)

Classificaiton
-Simple (90%)→ generalized < 15 min, no recur 24h
-Complex→ everything else
a) focal
b) > 15 min (some 10 min)
c) recur 24h
d) postictal neuro-deficit

Evaluation
-Based on classification, find T°C source
>Simple→ nothing specific

TTx
-Usually, self-limited (< 3 min)
-Otherwise, BZD, manage as SE
-Prophylaxis
>No ASM
>Antipyretics do not prevent FS
*Okay rescue BZD, if hs of febrile SE

Prognosis
-FS recurr→30%
-Epi, based on classification
>Simple, as general population

Amplitude-integrated EEG (aEEG)

Amplitude-integrated EEG (aEEG)

Applicability
-Mainly, new born
-No pattern for adults, except by 2 settings
a. post-cardiac arrest
b. NICU szs detection

Classifications
-Hellström-Westas→ 5 categories, term & preterm
-al Naqeeb→ 3 categories, only term
Explanation
1. CNV: LM 5–10 µV, UM 10–50 µV
2. DNV: LM < 5 µV, UM > 10 µV
3. BS: LM 0–2 µV, and bursts exceed 25 µV.
BS+: > 100 bursts per hour.
BS−: < 100 bursts per hour.
4. CLV: < 5 µV, with everything < 10 µV.
5. FT/isoelectric: no activity, < 5 µV.

Approach of preterm 
Adults
a. post–cardiac arrest
-CNV recovery time→ best predictor
>CNV within about 24 h predicted good outcome
>At least Fp1-Fp2

b. NICU szs detection
>recommended 1h windows, miss 30s szs

253. Accepted

252. Accepted

251. Accepted

Intermittent photic stimulation (IPS)

Intermittent photic stimulation (IPS)
Ancient Greece & Rome, 
Slave traders used a rotating potter's wheel as a provocative medical screening

❶Documentation
-If normal:
 >Symmetric posterior driving
 >No epileptiform discharges
 >No clinical correlate

-If abnormal:
 >Type of photoparoxysmal response (PPR)
 >Triggering frequency (range)
 >Clinical correlate: absent/ present (semiology)
 >Persistent beyond stimulation

❷Setup
-Informed consent
-Stop IPS, if discahrges
-Caution in genetic and photosensitive generalized epilepsies, especially JME
-Circular-reflector stimulator, at 30 cm from nasion and 0.7 intensity

❸Protocol
*IPS should be performed 3 min after HV, or before HV
1)Hz: 1→2→8→10→15→18→20→25→40→50→60
2)Eye: closure→closed→open
*Eye closure is the most provocative
3)If PRR occurs, stop ascending sequence
4)Restart from 60 Hz descending to determine range

❹Photic driving
-Occipital/post leads (MC)
-Usually: symmetric, post predominant, and non-epileptiform
-Components: harmonic (2x) and subharmonic (1/2)
E.g.: if 10 Hz stimuli, harmonic is 20 Hz response, and subharmonic 5 Hz

❺Photomyogenic response (PMR)
-Ocular artifact: frontal blinked related deflection
-PMR: 
>Time-locked frontotemporal muscle resposne
>Stops when stimulation ends

❻PPR
-Spike-wave or polyspike-wave discharges, often generalized; can persitent beyond stimulation
-PPRs range from post discharges to generalized responses

❼Considerations
ⓐ Does absent photic driving indicate abnormal brain function?→No
-Normal physiological occipital response
-Influenced by: retinal illumination and drowsiness

ⓑWhy IPS w/ eyes open, closure, and closed?→ ≠conditions
-Open→ preserved visual fixation
-Closure→ detect eye-closure sensitivity (ECS) in eyelid myoclonia (Jeavons syndrome)
>brief epileptiform discharges immediately after closing, within 1–3 seconds
-Closed→ fixation-off sensitivity (FOS), mainly in occipital epilepsies

Levetiracetam Versus Phenobarbital as First‑Line Therapy for Neonatal Seizures: A Meta‑analysis of Randomized Controlled Trials

Title: Levetiracetam Versus Phenobarbital as First‑Line Therapy for Neonatal Seizures: A Meta‑analysis of Randomized Controlled Trials

Authors: Ana Leticia Fornari Caprara, Jamir Pitton Rissardo

Conference: 2026 ANA Annual Meeting, San Diego, CA

OBJECTIVE
Phenobarbital remains the standard first‑line treatment (1LT) for neonatal seizures (NS) despite concerns regarding efficacy and safety. Levetiracetam has gained widespread use as an alternative, but randomized evidence is conflicting. We performed a meta‑analysis of randomized controlled trials (RCTs) comparing levetiracetam with phenobarbital as 1LT for NS.

METHODS
We systematically identified RCTs PubMed-indexed enrolling neonates treated with levetiracetam or phenobarbital as initial antiseizure medication (ASM). The primary outcome was seizure freedom (SF) within 24 hours. Secondary outcomes included 1LT failure, requirement for rescue ASM, adverse events (AEs), and mortality. Risk ratios (RRs) were pooled using a Mantel–Haenszel random‑effects model with REML. Heterogeneity was quantified using the I2 statistic. Numbers needed to treat (NNT) and harm (NNH) were estimated from absolute risk differences.

RESULTS
Six RCTs (levetiracetam=245; phenobarbital=216) were included. Levetiracetam did not significantly increase SF compared with phenobarbital (RR 1.23, 95% CI 0.86–1.76; I2=72%). On meta‑regression, trials using clinical seizure diagnosis demonstrated higher SF rates with levetiracetam (RR  1.38, 95% CI 1.01–1.88), whereas the single trial using continuous EEG‑confirmed seizures showed superior efficacy of phenobarbital (RR 0.30, 95% CI 0.17–0.54). 1LT failure (RR  0.87, 95% CI 0.52–1.44) and need for rescue ASM (RR 0.73, 95% CI 0.46–1.17) did not differ significantly between groups. Levetiracetam was associated with fewer AEs overall (RR 0.33, 95% CI 0.15–0.71), particularly hypotension (RR 0.30, 95% CI 0.13–0.68). No differences were observed between groups for respiratory depression (RR 0.63, 95% CI 0.32–1.25), bradycardia (RR 0.44, 95% CI 0.13–1.53), or mortality rates (RR 1.17, 95% CI 0.46–2.95). Levetiracetam increased SF by 3.3% (NNT ≈ 30), whereas phenobarbital increased hypotension by 9.1% (NNH ≈ 11).

CONCLUSIONS
Levetiracetam does not demonstrate consistent superiority over phenobarbital as 1LT for NS control. However, levetiracetam shows a more favorable short‑term safety profile. RCTs assessing different NS diagnoses are needed to confirm results.

Citation
Caprara AL, Rissardo JP. Levetiracetam Versus Phenobarbital as First‑Line Therapy for Neonatal Seizures: A Meta‑analysis of Randomized Controlled Trials. Ann Neurol 2026;100(Suppl 37):S160.